26 results about "Genipinine" patented technology

The invention is applicable to the technical field of biomedicine, and provides dipeptide-photosensitizer molecule co-assembled nanoparticles as well as a preparation method and application thereof. According to the invention, cationic diphenylalanine (CDP) and a biological cross-linking agent genipin are self-assembled to form a dipeptide carrier, and then the dipeptide carrier and a photosensitizer molecule chlorin e6 (Ce6) are co-assembled, so that nanoparticles with controllable size, controllable drug loading capacity and good biocompatibility are successfully prepared. The preparation method is simple and easy to implement, effectively solves the key problems that the traditional photosensitizer molecule Ce6 is poor in biocompatibility and easy to gather, not only can efficiently deliver Ce6, but also obviously improves the application safety and biocompatibility of Ce6. The Ce6 is almost free of dark toxicity under a dark condition, can play a strong photodynamic killing role under illumination, and greatly improves the possibility and application potential of the Ce6 in tumor photodynamic therapy by virtue of the flexible regulation and control advantages of the size and the drug loading capacity.

The invention relates to an application of genipin-1-beta-D gentiobioside in preparation of a medicine for treating chronic obstructive pulmonary disease. The genipin-1-beta-D gentiobioside is prepared into an aerosol inhalation solution, and the aerosol inhalation administration mode is adopted, so that the lung function in the chronic obstructive pulmonary disease can be improved, the content of inflammatory factors in lung tissues can be reduced, and the lung tissue injury can be relieved.

The present invention belongs to the field of organic synthesis technology and specifically relates to genipin derivatives, preparation methods, and applications thereof. The genipin derivatives provided by the present invention are structurally modified using genipin as a lead compound, attaching an unsaturated enol or alkynol group, and replacing the H atom on the C-1 hydroxyl group of genipin with 3-butene-1-ol, 4-pentene-1-ol, 5-hexene-1-ol, or 3-butyn-1-ol. The resulting four genipin derivatives containing unsaturated groups have excellent anti-inflammatory activity and are more suitable for preparing drugs for treating central nervous system inflammation.

The present invention discloses use of a male flower extract of Eucommia ulmoides Oliver in preparation of a food or a medicament for resisting muscle aging, belonging to the technical field of plant extracts. A main active ingredient of the male flower extract of Eucommia ulmoides Oliver is iridoids, and the composition of the iridoids includes aucubin, geniposide, geniposidic acid and asperuloside. The present invention reports for the first time that the male flower extract of Eucommia ulmoides Oliver and the iridoids contained therein have mitophagy activation activity and maintain normal mitochondrial function by effectively stimulating mitophagy. The extract has a relatively strong ability to prevent or alleviate aging-related muscle hypofunction, and has great application prospects in food, pharmaceutical and other fields.

A stabilized blue colorant is disclosed. The colorant includes a population of amino-acid-substituted genipin polymers having exclusively leucine, lysine, and arginine substitutions. The population includes a relative amino acid distribution of 5-90%leucine, 5-90%lysine, and 5-90%arginine. The stabilized blue colorant retains its blue color better than existing options. The colorant is made by a process that includes reacting genipin with the specific amino acids identified.

Embodiments described herein include semi-permanent inks (e.g., semi-permanent inks contains genipin, a genipin derivative, lawsone, a lawsone derivative, or combinations thereof); semi-permanent ink applicators; transfer mediums; silicone adhesives; and silicone mediums and kits containing two or more thereof. Some embodiments describe methods for applying an ink to skin as well as methods for increasing the darkness of a semi-permanent tattoo and / or increasing the longevity of a semi-permanent tattoo.

The application discloses a capillary electrophoresis quantitative analysis method of active ingredients of Wuobi Shanyao pills. The method comprises the following steps: pretreating and purifying the powder of the test sample Wuobi Shanyao pills by MSPD-SPE, and quantitatively determining the active ingredients of the test sample, i.e., loganin, geniposidic acid, trilobatin and verbascoside by CE-UV. The MSPD with high extraction efficiency, the SPE with strong purification capacity and the CE with less consumption of organic solvents are combined for the first time, and are used for green, efficient and accurate content determination of the four components (loganin, geniposidic acid, trilobatin and verbascoside) in Wuobi Shanyao pills. In the sample preparation process and in the CE separation and determination, the consumption of organic solvents is far less than the amount consumed in the prior art.

The invention belongs to the field of preparation of functional compounds, and particularly relates to a genipin derivative with an amino ether structure, a preparation method of the genipin derivative and application of the genipin derivative to reduction of uric acid. The genipin derivative is designed and synthesized by taking genipin as a lead compound and carrying out chemical modification on the genipin. In order to enhance the binding capacity of the genipin derivative and XOD, the C-14 site of genipin ether is substituted, an aromatic ring or aromatic heterocyclic group containing organic amine is introduced, and the chemical structure of the obtained genipin derivative is represented and confirmed through 1H NMR and 13C NMR. The geniposide derivative synthesized by the invention is subjected to XOD inhibitory activity screening. The invention provides a structural and theoretical basis for subsequent further research on a more efficient XOD inhibitor.

The application provides a genipin cross-linked selenium nanoparticle and a preparation method and application thereof, and belongs to the field of functional nanomaterials and intelligent nutrition delivery technology. The preparation method comprises the following steps: dissolving a protein substance in water to obtain a protein solution, adding a selenous acid compound, then adding vitamin C and genipin, performing cross-linking reaction, and performing dialysis on the obtained reaction solution to obtain the genipin cross-linked selenium nanoparticle. The application innovatively uses the concentration of genipin as a control switch, realizes active and accurate control of the release rate of selenium in the intestinal tract, realizes the treatment effect on colitis through instantaneous high-concentration release under a low-concentration selenium administration dose, and effectively solves the defect that the "nutrition-toxicity" dose range of selenium is narrow.

The invention discloses a pharmaceutical composition and application thereof. The pharmaceutical composition provided by the invention comprises the following active components in percentage by weight: 10-50% of geniposide, 10-50% of a surfactant, and 10-50% of a 10% to 50% of geniposide; 10% to 50% of genipin gentiobioside; 10 to 50 percent of crocin I and 10 to 50 percent of ursolic acid. The composition can effectively inhibit paralysis of tremor, improve the balancing capacity and grasping capacity of mice, reduce the content of interleukin-1beta and tumor necrosis factor-alpha, promote secretion of dopamine, reduce the content of malondialdehyde and improve the total antioxidant capacity in brain tissue. The compound has a good treatment effect on a Parkinson's disease model, so that the effect of treating the Parkinson's disease is expected to be greatly improved, and adverse reactions are reduced.

The invention discloses thermophilic beta-1, 4-glucosidase and an application of the thermophilic beta-1, 4-glucosidase. The base sequence of the thermophilic beta-1, 4-glucosidase is as shown in SEQ ID NO: 1. The thermophilic beta-glucosidase provided by the invention can be used for hydrolyzing p-nitrophenyl-beta-D glucopyranoside (pNPGlu), p-nitrophenyl-beta-D galactopyranoside (pNPGal), p-nitrophenyl-beta-D xylopyranoside (pNPXyl), p-nitrophenyl-alpha-D glucopyranoside (pNP alpha Glu), p-nitrophenyl-N-acetylglucosamine, geniposide, polydatin, glucosyltransferase, glucosyltransferase and the like. And salicin and arbutin. The optimum reaction temperature of the enzyme is 95 DEG C, and after the enzyme is treated at 70 DEG C for 24 hours, the residual enzyme activity is greater than 40%. In an n-hexyl alcohol-water phase (or n-caprylic alcohol-water phase), geniposide can be hydrolyzed into genipin, and industrial production of genipin is facilitated.

Use of genipin-1-β-D gentiobioside in the preparation of a drug for treating chronic obstructive pulmonary disease. Genipin-1-β-D gentiobioside is prepared into a solution for atomized inhalation. Using the administration mode of atomized inhalation can improve lung function in chronic obstructive pulmonary disease, reduce the content of inflammatory factors in lung tissue, and reduce damage to lung tissue.

A temporary tattooing ink is produced from concentrated genipin. In one embodiment, the concentrated genipin forms part of a solution. In another embodiment, the genipin is provided in a gel form which also includes a solvent and a thickening agent. Finally, an applicator is described into which genipin may be embedded for applying to a user's skin.

The invention belongs to the field of preparation of functional compounds, and particularly relates to a methylated aromatic substituted genipin derivative with a uric acid reducing effect as well as a preparation method and application of the methylated aromatic substituted genipin derivative. The genipin derivative synthesized by the invention is subjected to XOD inhibitory activity screening, and researches on in-vivo and in-vitro activity, uric acid reduction and XOD inhibitory activity, anti-inflammatory activity and anti-fibrosis activity show that the derivative shows relatively high XOD inhibitory activity; oxidative stress is relieved by inhibiting XOD activity at the liver, so that liver inflammation is inhibited. The invention provides a structural and theoretical basis for subsequent further research on a more efficient XOD inhibitor.

According to the oleic acid-geniposide composite preparation and the application thereof, a mixed system of oleic acid and geniposide is constructed and acts on PC12 cells induced by hydrogen peroxide to generate oxidative damage, and the result shows that compared with cells treated by singly using geniposide with the same concentration, the oleic acid-geniposide composite preparation has the advantages that the effect is good, and the cost is low. The mixed system can obviously improve the survival rate of PC12 cells, and the obvious effect is not observed after linoleic acid and linolenic acid are respectively mixed with geniposide. The invention clarifies that oleic acid can enhance the protective effect of geniposide on oxidative damage cells, and provides a brand new thought and technical support for developing products for resisting oxidative damage of cells.

The present application relates to topical compositions comprising a compound capable of covalently binding to the skin and an excipient suitable for topical application wherein the compound capable of covalently binding to the skin is a compound of formula (I) or a tautomer and / or a pharmaceutically acceptable salt thereof, wherein R1 represents hydrogen or a protecting group that is hydrolysable under physiological conditions upon application of the topical composition to the skin; wherein L1, L2 and L3, independently of each other, represent a linking group or are absent, and wherein A1, A2 and A3, independently of each other, represent: a) a C1-C30 moiety, H, hydroxyl, amino or halogen, or b) a C1-C60 moiety or a polymeric moiety; wherein at least one of A1, A2 and A3 is a C1-C60 moiety or a polymeric moiety of group b); wherein the C1-C60 portion or polymeric portion of group b): b1) is configured to act as a skin moisturizer, an insecticide, a skin whitening agent or a drug; and / or b2) is configured to act as a skin moisturizer, an insecticide, a skin whitening agent, a fragrance or a drug upon cleavage from the 3, 4-dihydro-2H-pyran moiety; and wherein L1-A1 and L2-A2 do not represent a moiety comprising an unsaturated C-C or C-N bond at the alpha position of the carbon atoms marked as "a" and "b", respectively. (I);

The invention relates to the technical field of medical materials, in particular to a coloring agent for endoscopic surgery and a preparation method and application thereof.The coloring agent is an acetyl-GPLGIRG-genipin enzyme activated precursor, the acetyl-GPLGIRG-genipin enzyme activated precursor is obtained through a reaction of acetylated GPLGIRG polypeptide and genipin, and the GPLGIRG polypeptide and the genipin are used for preparing the coloring agent for endoscopic surgery. The genipin is connected to the carbon end of the acetylated GPLGIRG polypeptide. Rapid, clear and lasting targeted blue labeling of a lesion area is realized by using a specific cross-linking reaction of a genipin component and a protein amino group and utilizing biochemical difference of a lesion tissue and a normal tissue on a microstructure. The problem that a traditional staining agent cannot specifically mark lesions is solved, a pad formed by lifting liquid under mucous membranes is more stable and durable due to the cross-linking characteristic of the staining agent, and double advantages are provided for endoscopic surgery.

This invention relates to the field of cellular drug screening technology, specifically to a genipin derivative, its synthesis method, and its uses. The genipin derivative is an N-substituted genipin lactam derivative or a cyclopentenepyridine derivative; the N-substituted genipin lactam derivative is a compound represented by general formula (I), and the cyclopentenepyridine derivative is a compound represented by general formula (II); wherein R is selected from any one of hydrogen, alkyl, phenyl, and aralkyl. This invention uses genipin as a lead compound, modifies the core structure, and performs cellular activity screening to identify lead compounds with good activity and low toxicity, providing a foundation for subsequent research on the anti-inflammatory effects of genipin.

The present invention belongs to the technical field of organic synthesis, and specifically relates to a 1-S-alkyl genipin derivative, a preparation method thereof, and an application thereof. The present invention provides a 1-S-alkyl genipin derivative, the structure of which is shown in Formula I. The 1-S-alkyl genipin derivative provided by the present invention has good stability and activity. The preparation method provided by the present invention has simple steps, is easy to operate, has high feasibility, and has good prospects for industrial application. The present invention also provides the use of the 1-S-alkyl genipin derivative described in the above scheme or the 1-S-alkyl genipin derivative obtained by the preparation method described in the above scheme in the preparation of anti-inflammatory drugs and drugs for preventing and treating central nervous system diseases. The 1-S-alkyl genipin derivative provided by the present invention has good stability and activity and can be used to prepare anti-inflammatory drugs and drugs for preventing and treating central nervous system diseases. #imgabs0#

The present application provides topical compositions comprising genipin derivatives of formula (I), # imgabs0, which are useful as colorants, for example, in semi-permanent tattoo.

The present application relates to a kind of mitochondrial uncoupling inhibitor sustained-release nanodots and its preparation method and application in type 2 diabetes, belong to nanopharmaceutical technical field.The preparation method of the present application, glycine and genipin occur Schiff reaction to prepare and obtain sustained-release nanodot, it is monodisperse spherical structure and has surface negative charge, it can slowly release genipin under physiological conditions, fully exert its mitochondrial protective effect.The mitochondrial uncoupling inhibitor sustained-release nanodot prepared in the present application can significantly improve mitochondrial membrane potential and increase cell ATP content, effectively inhibit IL-1 beta and mtDNA release under palmitic acid stimulation, effectively inhibit IL-1 beta and PA stimulate STING inflammatory pathway activation, significantly reduce islet beta cell apoptosis, significantly alleviate endoplasmic reticulum stress, significantly reduce T2DM mouse blood glucose improve its glucose tolerance and insulin sensitivity, with good biocompatibility.

An application of a genipin beta-methyl derivative, Gen-17, in a preparation of a drug for prevention and treatment of acute severe pneumonia is provided. A mouse model of acute lung injury (ALI) is first used to simulate acute severe pneumonia of human beings, and preventive and therapeutic effects of the Gen17 on mice with ALI are systematically evaluated. The results show that the Gen17 can significantly alleviate pathomorphological damage of lung tissues of ALI mice induced by lipopolysaccharide, and inhibit inflammatory reaction and oxidative stress of the lung tissues. A protective mechanism of the Gen-17 on the lung of the ALI mice is that an anti-inflammatory role is played by inhibiting NF-κB and MAPK signaling pathways, and an anti-oxidative role is played by activating Keap1 / Nrf2 / HO-1 signaling pathways. It can provide some experimental basis for the application of the Gen-17 in prevention and treatment of acute severe pneumonia.

The invention relates to application of mitochondrial uncoupling inhibitor sustained-release nanodots in preparation of drugs for treating inflammatory bowel diseases, and belongs to the technical field of new application of nano-drugs. The technical problem that in the prior art, a mitochondrial uncoupling inhibitor genipin is easily cross-linked with digestive tract protein after being orally taken and is difficult to accurately reach an intestinal lesion part, so that the curative effect cannot be fully exerted is solved. According to the application of the mitochondrial uncoupling inhibitor sustained-release nanodot in preparation of the medicine for treating the inflammatory bowel disease, the mitochondrial uncoupling inhibitor sustained-release nanodot prepared through the Schiff reaction of glycine and genipin can be kept stable in the gastric juice environment, genipin is slowly released in the intestinal environment, and the effect of treating the inflammatory bowel disease is achieved. And the protective effect of intestinal epithelial cell mitochondria is fully exerted.

The present application provides topical compositions comprising genipin derivatives of formula (I), which are useful as colorants, for example, in semi-permanent tattoo.

The invention belongs to the field of nerve injury repair scaffold materials, and particularly relates to a preparation method of a W1.33Ci-MXene layered transition metal carbon / nitride-chitosan nerve conduit. Comprising the following steps: S1, preparing a chitosan / acetic acid solution by taking chitosan as a solute and acetic acid as a solvent; the preparation method comprises the following steps: preparing a W1.33Ci-MXene / genipin solution by taking W1.33Ci-MXene and genipin as solutes and pure water as a solvent; s2, mixing the two solutions, injecting the mixed solution into a catheter mold, and gelatinizing the mixed solution; and S3, performing low-temperature freezing, and then performing freeze drying immediately. In-vitro experiments prove that the nerve conduit provided by the invention can promote differentiation of a PC12 cell line through temperature change induced by a photothermal effect by using near infrared (NIR) to stimulate the nerve conduit, so that the nerve conduit has the capability of forming synapses.

The invention provides genipin cross-linked selenium nano-particles and a preparation method and application thereof, and belongs to the technical field of functional nano-materials and intelligent nutrition delivery, the preparation method comprises the following steps: dissolving a protein substance in water, hydrating to obtain a protein solution, adding a seleninic acid compound, then adding vitamin C and genipin, and uniformly stirring to obtain the genipin cross-linked selenium nano-particles. And carrying out a cross-linking reaction, and dialyzing the obtained reaction liquid to obtain the genipin cross-linked selenium nanoparticles. The genipin concentration is innovatively used as a regulation switch, active and accurate control over the release rate of selenium in the intestinal tract is achieved, namely, the treatment effect on colitis can be achieved through instant high-concentration release under the condition of the low-concentration selenium administration dosage, and the defect that the nutrition-toxicity dosage range of selenium is narrow is effectively overcome.